# Quantum X Labs Inc.

**QXL**

Nasdaq; business equipment; SIC 7372, Services-Prepackaged Software; CIK 0000797542


# None

### No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $10.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | late filer, thin data<br>not computable: dilution, distress |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Mar 27, 2026<br>223 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $4.12<br>2026-11-02; market equity $89.0M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 27, 2026*

Inc. (the "Registrant", "Viewbix" or the "Company") was incorporated in the State of Delaware on August 16, 1985, under a predecessor name, The InFerGene Company ("InFerGene Company"). On August 25, 1995, a wholly owned subsidiary of InFerGene Company merged with Zaxis International, Inc., an Ohio corporation, which following such merger, the surviving entity, InFerGene Company, changed its name to Zaxis International, Inc. ("Zaxis"). Our principal executive offices are located at 3 Hanehoshet St, Building B, 7th floor, Tel Aviv, Israel 6971068. Our website address is https://view-bix.com/ and our telephone number is + 972 9-774-1505.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 45.8** | | | | | | |
| Gross profitability | not computable | 28.6% | | | | |

*latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | (23.1%) | 11.2% | 89.3 | 132 | 2025-12-31 |
| Accruals ratio | (100.9%) | (7.3%) | 2.3 | 617 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.3 pts | | | |
| *five annual gross margins are required; found 3* | | | | | |
| **Solvency, sleeve percentile 95.2** | | | | | |
| Twelve-month failure probability | not computable | 0.05% | | | |
| *liabilities and a nearby cover-page share count are required at 2026-06-30* | | | | | |
| Altman Z double-prime | not computable | 2.16 | | | |
| *latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31* | | | | | |
| Net debt to EBITDA | not computable | 1.09x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | 3.77x | | | |
| *required facts have no common fiscal period end* | | | | | |
| Current ratio | 0.41x | 2.01x | 95.2 | 662 | 2025-12-31 |
| **Growth and financing, sleeve percentile 98.7** | | | | | |
| Revenue growth, three-year compound | not computable | 6.4% | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | |
| Free cash flow growth, three-year compound | not computable | 17.7% | | | |
| *four consecutive annual FCF observations are required; found 5* | | | | | |
| Reinvestment rate | not computable | 13.3% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | (44.7%) | 5.1% | 98.7 | 559 | 2025-12-31 |
| Net share issuance, one year | not computable | 0.5% | | | |
| *raw and split-adjusted prices do not align at 2025-03-20* | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Late filer | found 2 NT 10-K/Q filings in the last eight quarters |
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-02 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (66.1%) | (2.0%) | 9 |
| Distance from 52-week high | (71.7%) | (33.1%) | 13 |
| EBIT to enterprise value | (2.6%) | 1.7% | 26 |
| Free cash flow yield | 1.8% | 2.8% | 38 |
| Book value to price | 0.31 | 0.28 | 55 |
| Sales to price | 0.32 | 0.31 | 51 |
| Composite equity issuance, five years | not computable | 4.2% | |
| Relative strength against the sector, log excess return | (1.35) | (0.29) | 9 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $2.4M |
| Operating cash flow, four quarters | -$3.6M |
| Months of runway | 8.1 |
| Days since last periodic filing | 84 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $137,739 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $41,000 | 2021-12-31 | 2022-03-17 | 10-K | 22-007150 |
| 2 | assets | us-gaap:Assets | $51.3M | 2021-12-31 | 2023-03-24 | 10-K | 23-008765 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$2.2M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$13.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$39,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 6 | total debt | us-gaap:LongTermDebt | $2.5M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 7 | book equity | us-gaap:StockholdersEquity | $5.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 9 | total debt | us-gaap:LongTermDebt | $6.6M | 2024-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 10 | book equity | us-gaap:StockholdersEquity | $5.8M | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $24,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 12 | net income | us-gaap:NetIncomeLoss | -$19.3M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | -$2.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 14 | assets | us-gaap:Assets | $10.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 15 | assets | us-gaap:Assets | $22.0M | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 16 | current assets | us-gaap:AssetsCurrent | $153,000 | 2018-12-31 | 2020-03-20 | 10-K | 20-004372 |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $833,000 | 2018-12-31 | 2020-03-20 | 10-K | 20-004372 |
| 18 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$13.6M | 2018-12-31 | 2020-03-20 | 10-K | 20-004372 |
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$578,000 | 2018-12-31 | 2020-03-20 | 10-K | 20-004372 |
| 20 | book equity | us-gaap:StockholdersEquity | -$721,000 | 2018-12-31 | 2021-03-16 | 10-K | 21-006123 |
| 21 | assets | us-gaap:Assets | $158,000 | 2018-12-31 | 2020-03-20 | 10-K | 20-004372 |
| 22 | liabilities | us-gaap:Liabilities | $975,153 | 2018-12-31 | 2019-03-29 | 10-K | 19-004164 |
| 23 | depreciation amortization | us-gaap:Depreciation | $67,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 24 | current assets | us-gaap:AssetsCurrent | $1.7M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $4.1M | 2025-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 26 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $26.9M | 2024-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 27 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $79.6M | 2023-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 28 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $96.6M | 2022-12-31 | 2024-03-25 | 10-K | 24-011132 |
| 29 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $45.2M | 2021-12-31 | 2023-03-24 | 10-K | 23-008765 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1,000 | 2024-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 31 | depreciation amortization | us-gaap:Depreciation | $115,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 32 | operating income | us-gaap:OperatingIncomeLoss | -$837,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 33 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$3.4M | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 34 | income tax | us-gaap:IncomeTaxExpenseBenefit | $131,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 35 | current assets | us-gaap:AssetsCurrent | $7.8M | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 36 | current liabilities | us-gaap:LiabilitiesCurrent | $12.9M | 2024-12-31 | 2026-03-27 | 10-K | 26-013205 |
| 37 | current assets | us-gaap:AssetsCurrent | $17.8M | 2023-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 38 | current liabilities | us-gaap:LiabilitiesCurrent | $19.8M | 2023-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 39 | assets | us-gaap:Assets | $43.3M | 2023-12-31 | 2025-03-21 | 10-K | 25-011100 |
| 40 | assets | us-gaap:Assets | $63.7M | 2022-12-31 | 2024-03-25 | 10-K | 24-011132 |
| 41 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 13,336,392 | 2026-03-26 | 2026-03-27 | 10-K | 26-013205 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 5,296,945 | 2025-03-20 | 2025-03-21 | 10-K | 25-011100 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.